Biotechnology

A new $50M fund unites venture capital with Canada's top cancer charities, aiming to fast-track lab discoveries into life-saving patient treatments.

With new strategic financing and powerhouse board appointments, 4D Path is accelerating its novel AI platform that predicts cancer treatment success from a single slide.

Germany's startups attracted €1.7B in Q1 2026, fueled by US investors and a massive bet on artificial intelligence, signaling a new era for its ecosystem.

Promising data for its lead drug budoprutug has Climb Bio on a path to potentially redefine treatment for a range of debilitating autoimmune diseases.

A novel gene therapy aims to cross the blood-brain barrier, offering new hope for Tuberous Sclerosis Complex, thanks to a powerful new partnership.

A new biotech emerges with a promising, late-stage gene therapy for Sanfilippo syndrome, offering a potential lifeline for children with no other options.

With $255M raised, Diagonal Therapeutics brings on a seasoned CFO to advance its novel antibody treatments for rare genetic diseases into the clinic.

Jeito Capital appoints top talent and BD partners, signaling a strategic shift in biopharma investing where deep operational expertise is now king.

A new drug, CS-1103, earns FDA Fast Track to combat fentanyl overdoses by binding and removing the opioid, a potential game-changer over naloxone.

A new 'dream team' of experts will guide AI development to create non-invasive tools for a deadly lung disease, aiming to replace painful procedures.

UK biotech Cytospire Therapeutics secures major funding to push its safer, more selective gamma delta T-cell engager into clinical trials for solid tumors.

UK biotech Cytospire secures a major Series A to bring its novel pan-gamma delta T cell engagers, targeting tough solid tumors, into clinical trials.

A top European fertility network is rolling out AI to select embryos, promising higher success rates but sparking debate on the future of data-driven parenthood.

Beyond its first blockbuster, CRISPR Therapeutics reveals a deep pipeline for autoimmune and liver diseases, backed by a strong Q1 balance sheet.

The biotech's blockbuster Nasdaq debut provides crucial capital for its promising pipeline, offering new hope for patients with severe bleeding conditions.

A landmark deal brings a promising, but unapproved, therapy for a rare blinding disease to French patients via a special compassionate use program.

ProBio's new Viral Vector Packaging Test promises to accelerate development and reduce risks, addressing major hurdles in bringing cell and gene therapies to market.

A major investment in natural killer cell immunotherapy aims to revolutionize treatment for Canada's most fatal women's cancer after decades of stagnation.

LANGLARA, a new Lantus biosimilar, gains FDA approval, promising more affordable diabetes care. But it faces a tough fight in a competitive market.

The new Gibco CTS DynaXS bioreactor aims to unlock scalable production, making life-saving cell therapies more accessible and affordable for patients.